1. Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, China;
2. Clinical Lab Diagnosis, China-Japan Union Hospital, Jilin University, Changchun, China;
J Cancer. 2016 Jan 29;7(4):477-83. doi: 10.7150/jca.13870. eCollection 2016.
To screen biomarkers to differentiate early-stage colorectal cancer (CRC) from benign colorectal disease (BCD) and healthy controls.
MATERIALS & METHODS: Quantitative and qualitative analysis of C16:1, C18:3, C18:2, C18:1, C20:4, and C22:6 in 185 healthy controls, 55 patients with BCD, and 139 patients with CRC was performed. Comparisons of their levels in between CRC patients, BCD patients, and healthy controls were performed using Mann-Whitney U test.
Serum levels of C16:1, C18:3, C18:2, C18:1, C20:4, and C22:6 in CRC patients were significantly decreased compared with healthy controls and BCD patients. A combination of C16:1, C18:2, C20:4, and C22:6 has excellent diagnostic performance to differentiate early-stage CRC patients from healthy controls plus BCD patients, with an AUC of 0.926, a sensitivity of 84.6%, and a specificity of 89.8%.
Serum levels of C16:1, C18:2, C20:4, and C22:6 could be diagnostic indicators of early-stage CRC patients.
筛选生物标志物以区分早期结直肠癌（CRC）与良性结直肠疾病（BCD）和健康对照。
对 185 例健康对照者、55 例 BCD 患者和 139 例 CRC 患者的 C16:1、C18:3、C18:2、C18:1、C20:4 和 C22:6 进行定量和定性分析。使用 Mann-Whitney U 检验比较 CRC 患者、BCD 患者和健康对照者之间的水平差异。
与健康对照者和 BCD 患者相比，CRC 患者血清中的 C16:1、C18:3、C18:2、C18:1、C20:4 和 C22:6 水平显著降低。C16:1、C18:2、C20:4 和 C22:6 的组合具有出色的诊断性能，可以区分早期 CRC 患者与健康对照者和 BCD 患者，AUC 为 0.926，灵敏度为 84.6%，特异性为 89.8%。
血清 C16:1、C18:2、C20:4 和 C22:6 水平可能是早期 CRC 患者的诊断指标。
